for people ages 18 years and up (full criteria)
study started
estimated completion
Principal Investigator
by Pamela Munster (ucsf)
Headshot of Pamela Munster
Pamela Munster



This trial will look at a drug called SGN-STNV to find out whether it is safe for patients with solid tumors. It will study SGN-STNV to find out what its side effects are. A side effect is anything the drug does besides treating cancer. It will also study how well SGN-STNV works to treat solid tumors. The study will have two parts. Part A of the study will find out how much SGN-STNV should be given to patients. Part B will use the dose found in Part A to find out how safe SGN-STNV is and if it works to treat certain types of solid tumors.

Official Title

A Phase 1 Study of SGN-STNV in Advanced Solid Tumors


The study will include dose escalation (Part A) and dose expansion (Part B), with multiple disease-specific cohorts and a biology cohort in dose expansion. The biology cohort will be gated based on data generated from other expansion cohorts and will require additional biopsies. At the completion of dose escalation, up to 5 disease specific expansion cohorts and 1 biology expansion cohort may be activated by the sponsor in consultation with the Safety Monitoring Committee (SMC). Expansion cohorts in Part B will enroll subjects with selected tumors that are eligible for enrollment in Part A. The dose(s) to be examined in Part B will be at or below the maximum tolerated dose and/or the recommended dose determined in Part A. The recommended dose and/or schedule may differ between cohorts.


Carcinoma, Non-Small Cell Lung HER2 Negative Breast Neoplasms Ovarian Neoplasms Uterine Cervical Neoplasms Endometrial Neoplasms Esophageal Neoplasms Gastroesophageal Junction Carcinoma Stomach Neoplasms Colorectal Neoplasms Exocrine Pancreatic Adenocarcinoma Appendiceal Adenocarcinoma Pseudomyxoma Peritonei NSCLC Non-Small Cell Lung Cancer HER2-Negative Breast Cancer High-Grade Serous Ovarian Cancer HGSOC Ovarian Cancer Cervical Cancer Endometrial Cancer Esophageal Cancer Gastric Cancer GEJ Carcinoma Colorectal Cancer Seattle Genetics Carcinoma Neoplasms Adenocarcinoma Breast Neoplasms Carcinoma, Non-Small-Cell Lung SGN-STNV


You can join if…

Open to people ages 18 years and up

You CAN'T join if...

  • History of another malignancy within 3 years before the first dose of study drug, or any evidence of residual disease from a previously diagnosed malignancy.
  • Known active central nervous system metastases
  • Carcinomatous meningitis
  • Previous receipt of monomethylauristatin E (MMAE)-containing drugs
  • Pre-existing neuropathy ≥ Grade 2 per the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0
  • Any uncontrolled ≥ Grade 3 (per the NCI CTCAE, Version 5.0) viral, bacterial, or fungal infection within 2 weeks prior to the first dose of SGN-STNV

There are additional inclusion and exclusion criteria. The study center will determine if criteria for participation are met.


  • University of California at San Francisco accepting new patients
    San Francisco California 94158 United States
  • Angeles Clinic and Research Institute, The accepting new patients
    Los Angeles California 90025 United States

Lead Scientist at UC Cancer

  • Pamela Munster (ucsf)
    Professor, Medicine, School of Medicine. Authored (or co-authored) 136 research publications


accepting new patients
Start Date
Completion Date
Seagen Inc.
Phase 1 research study
Study Type
Last Updated